View on Mankind Pharma IPO from S Ranganathan, LKP Securities
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Below is View on Mankind Pharma IPO by S Ranganathan, Head of Research at LKP Securities
Fast Growing India Centric Mankind Pharma truly deserves credit for bringing back life into the Primary Market during CY 2023 with a stellar listing which provided a 30% return to Retail Investors and the icing on the cake was the allotment itself wherein almost all retail investors were allotted the shares.
Above views are of the author and not of the website kindly read disclaimer
.jpg)
Tag News
We anticipate immense potential benefits from the upcoming Sovereign Gold Bond Tranche in FY...
